BIIB Biogen, Inc.

233.011.23 (+0.53%)
Close: June 18, 2019

234.701.69 (+0.73%)
Pre-market

Quote

Previous Close
$233.01
Day Range
$232.54-$237.75
52 Week Range
$216.12-$388.67
Volume
1,644,971
Avg Volume
1,696,610
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$45.18B
Enterprise Value (EV)
$46.54B
PE Ratio
10.02
EV/EBITDA
8.01
Price/Sales
3.66
Price/Book
3.46
PEG Ratio
0.65

Financials

Revenue
$12.05B
Gross Profit
$9.86B
EBITDA
$5.81B
EPS, ttm
$23.26
Profit Margin
36.76%
Revenue/Employee
$1.55M
Next Earnings Date
7/23/2019 (34 days)
Debt to Equity
46%
Debt
$4.90B
Cash
$3.54B
Net Debt
$1.36B

Performance

Beta
0.91
200 Day Moving Avg
$296.52
50 Day Moving Avg
$229.72
52 Week Change
-19.83%
YTD Change
-23.40%
1 Month Change
0.44%
3 Month Change
-28.82%
6 Month Change
-21.36%
1 Year Change
-19.83%
2 Year Change
-9.35%
5 Year Change
-16.88%

Share Count

Shares Outstanding
193.9M
Float
193.5M
Restricted Shares
365.6K
Restricted Shares, %
0.19%

Biogen, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Michel Vounatsos

Website: http://www.biogen.com

Description: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Employees: 7,800